Shennon Biotechnologies

Shennon Biotechnologies (often styled ShennonBio) is a privately held biotechnology company headquartered in San Francisco, California, near the UCSF Mission Bay campus. The company is developing next-generation T-cell engagers and other precision immunotherapies for solid tumors, built on functional biology at the single-cell level. Its scientific foundation dates to 2015, when members of the founding team began work at Harvard University on the challenge of high-throughput profiling of dynamic cell-cell interactions. The company's core technology was invented by Li Sun, PhD, who serves as Founder, President and Chief Technology Officer and was formerly a venture capital partner at Foundation Capital. ShennonBio's approach is organized around a unified technology engine that integrates target discovery, ultra-high-throughput functional screening, computational optimization, and predictive safety assessment. The engine comprises three proprietary platforms: PINTRA for target discovery, TCELERATOR for microfluidics-driven functional screening of binders, and SERIS for computational therapeutics design and predictive safety assessment. According to the company, TCELERATOR can profile more than 10 million single-cell interactions in a single experiment, identifying functional leads far faster than conventional sequential binder testing. This engine is grounded in proprietary human tumor datasets spanning more than 10,000 tumor samples and more than 11 million single cells, built through a network of academic and clinical collaborators across 15 institutions. The company operates approximately 6,000 square feet of laboratory and office space in San Francisco, including wet labs for in vitro pharmacology, a clean room for in-house microchip fabrication, and engineering tools such as a CNC machine, injection molder, and 3D printers. Its interdisciplinary team includes immunologists, protein engineers, computational biologists, and microfluidic engineers. ShennonBio's initial therapeutic focus is next-generation T-cell engagers directed against both surface and intracellular cancer targets, with the goal of developing more selective and safer therapeutics. The company is private and actively hiring for scientific roles in San Francisco.

Shennon Biotechnologies traces its origins to 2015, when its founding team began working at Harvard University to address a longstanding challenge in high-throughput profiling of dynamic cell-cell interactions. That early work led to the core technology that would later underpin the company. Li Sun, PhD, a former venture capital partner at Foundation Capital, invented the core technology and went on to serve as Founder, President and Chief Technology Officer. The company was established in San Francisco, California, near the UCSF Mission Bay campus, where it operates approximately 6,000 square feet of laboratory and office space. Over time, the initial technology evolved into a broader platform combining microfluidics, computational biology, and translational immunology. ShennonBio describes this as a unified engine that integrates target discovery, functional screening of binders, computational optimization, and predictive safety assessment. The engine is built on three proprietary platforms: PINTRA for target discovery, TCELERATOR for ultra-high-throughput microfluidics-driven functional screening, and SERIS for computational therapeutics design and predictive safety assessment. According to the company, TCELERATOR can profile more than 10 million single-cell interactions at once, identifying functional leads in a single experiment, whereas conventional discovery tests binders sequentially over months. The platform is grounded in proprietary human tumor datasets spanning more than 10,000 tumor samples and more than 11 million single cells, assembled through an expanding network of academic and clinical collaborators across 15 institutions. ShennonBio's therapeutic focus is on next-generation T-cell engagers for solid tumors, targeting both surface and intracellular cancer targets. The company aims to develop more selective and safer therapeutics by combining its functional screening capabilities with computational engineering and translational immunology. Its interdisciplinary team includes immunologists, protein engineers, computational biologists, and microfluidic engineers working in an open office environment. The company is privately held and continues to recruit scientific talent in San Francisco.

• 2015

  Founding team begins work at Harvard University on high-throughput profiling of dynamic cell-cell interactions, leading to the core technology.

• Company established in San Francisco near UCSF Mission Bay with approximately 6,000 square feet of laboratory and office space.

• Development of unified technology engine comprising PINTRA, TCELERATOR, and SERIS platforms.

Precision immunotherapies for solid tumors built on functional biology at the single-cell level, enabled by an integrated technology engine.

• TCELERATOR

  Ultra-high-throughput microfluidics-driven functional screening platform that profiles more than 10 million single-cell interactions at once.

• PINTRA

  Target discovery platform within ShennonBio's unified engine.

• SERIS

  Computational therapeutics design and predictive safety assessment platform.

1. 1Shennon Bioshennonbio.com
2. 2Teamshennonbio.com
3. 3Technologyshennonbio.com
4. 4Shennon Biotechnologieswikidata.org